AAA
CRSP icon

Affinity Asset Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Affinity Asset Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200,000
Closed -$9.73M – 103
2025
Q2 		$9.73M Buy
+200,000
New +$7.74M 1.33% 25
2024
Q2 		– Sell
-65,000
Closed -$4.43M – 106
2024
Q1 		$4.43M Buy
+65,000
New +$4.65M 0.55% 54
2022
Q3 		– Sell
-70,000
Closed -$4.25M – 68
2022
Q2 		$4.25M Buy
70,000
+15,000
+27% +$882K 1.79% 22
2022
Q1 		$3.45M Buy
+55,000
New +$3.45M 0.55% 29

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Affinity Asset Advisors's CRSP Position: Q2 2026 in Review

Affinity Asset Advisors reduced its CRISPR Therapeutics (CRSP) stake by 33% in Q2 2026, selling an estimated $2.64M and leaving 100,000 shares worth $5.45M. The position accounts for 0.25% of the portfolio, ranked #75.

Affinity Asset Advisors first reported a position in CRSP in Q4 2020 and has held it in 3 quarters since. The position peaked at $7.14M in Q1 2026. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Affinity Asset Advisors held 100,000 shares of CRISPR Therapeutics worth $5.45M as of Q2 2026.
  • Affinity Asset Advisors sold 50,000 CRISPR Therapeutics shares in Q2 2026, an estimated $2.64M.
  • CRISPR Therapeutics made up 0.25% of Affinity Asset Advisors's portfolio in Q2 2026, its #75 holding.
  • Affinity Asset Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • Affinity Asset Advisors's CRISPR Therapeutics position peaked at $7.14M in Q1 2026.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.